As medicine moves forward—making advances in prevention, detection, care delivery and more—cancer marches on, killing nearly 2 million Europeans every year. As one would expect, the reasons are as complex as cancer itself and one of the most significant reasons is variability in care. Here, we explore some of the reasons behind the variation and how AI may be able to help.
Data is proliferating and EHRs are a key source of data. Fewer doctors are practicing oncology, cancer is spreading, and more care is needed. Clinical research keeps growing.
Combining real world evidence with artificial intelligence may improve visibility of treatment options for oncologists
With an impending shortage of oncologists, an exponentially growing body of literature, and a steady stream of new cancer cases, it’s no surprise that one study found significant cancer health disparities in the US.
IBM Watson® for Clinical Trial Matching uses artificial intelligence (AI) and natural language processing technology to help cancer centers identify potential candidates for trials and help clinicians find potential clinical trials for their patients.
Watson is the only AI technology tackling a wide range of the world’s biggest healthcare challenges including cancer, diabetes, drug discovery and more. In oncology, Watson is at work supporting cancer care in more than 150 hospitals in 11 countries, and a large, growing body of evidence supports the use of Watson in healthcare.
Clinical Trial Matching: The frustration of matching patients to cancer research begins with data issues — and can end with artificial intelligence
If you work in oncology or cancer clinical trial coordination in the US, you already know the numbers don’t always work in your or your patients’ favor.
You know the odds when it comes to patient recruitment for clinical trials – we’re trying to improve them
Every year in the United States 1.6 million Americans develop cancer, joining nearly 14 million fellow citizens in the fight against the disease.
We at IBM have a lot to be proud of, including our pioneering work with Watson Health. Unfortunately, some media reports, including an August 11th story published by The Wall Street Journal, distort and ignore facts when suggesting IBM has not made “enough” progress on bringing the benefits of AI to healthcare.
I would like to provide an update on Watson Health and address a few misperceptions. If you only read certain media reports recently, you would have an incomplete and inaccurate perspective, especially as it relates to our Watson for Oncology product.
In 2012, an estimated 14.1 million people were diagnosed with cancer worldwide, and my country, Slovakia, ranks 22nd in terms of overall cancer frequency. As the incidence of cancer continues to grow and time constraints on oncologists intensify, the need for research and treatment innovation is more important than ever. The good news for patients […]
Hearing diverse opinions from multiple oncologists is an important part of a patient’s journey, what’s often referred to as getting a second – or third – opinion. And cancer docs, too, frequently consult with one another to confirm a decision or provide a new idea. That’s understandable because cancer is a complex and sometimes elusive […]